| Trial ID: | L0357 |
| Source ID: | NCT05750875
|
| Associated Drug: |
Loratadine
|
| Title: |
Gabapentin Versus Loratadine in Uremic Pruritus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Pruritus|Uremia|Chronic Kidney Diseases
|
| Interventions: |
DRUG: Loratadine|DRUG: Gabapentin
|
| Outcome Measures: |
Primary: Mean reduction in pruritus score, from baseline till 4 weeks, as measured on a numerical rating scale., Reduction in pruritus score as measured on a numerical rating scale, numbered between '0' (corresponding to no itch) and '10' (the worst imaginable itch)., Four weeks | Secondary: Mean reduction in Dermatology Life Quality Index Questionnaire score, from baseline till 4 weeks., Dermatology Life Quality Index Questionnaire score ranging from from 0 (no impairment of life quality) to 30 (maximum impairment)., Four weeks|Comparison of side effects of gabapentin and loratadine, as reported by the participants., Four weeks
|
| Sponsor/Collaborators: |
Sponsor: King Edward Medical University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
64
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2022-05-01
|
| Completion Date: |
2022-10-31
|
| Results First Posted: |
|
| Last Update Posted: |
2023-03-16
|
| Locations: |
King Edward Medical University/Mayo Hospital, Lahore, Punjab, 54000, Pakistan
|
| URL: |
https://clinicaltrials.gov/show/NCT05750875
|
